Jason Wilson - Reata Pharmaceuticals CFO and Vice President Strategy
| RETADelisted Stock | USD 172.36 0.02 0.01% |
President
Mr. Jason Dauglas Wilson is the Chief Financial Officer, Executive Vice President, Strategy of Reata Pharmaceuticals Inc. Prior to joining Reata, he held positions as Vice President, Finance Corporationrationrate Controller at Caris Diagnostics and as a Senior Manager in the healthsciences group at Ernst Young LLP. He currently serves on the board of directors of CytoSen Therapeutics, a private company since 2018.
| Age | 48 |
| Tenure | 6 years |
| Professional Marks | MBA |
| Phone | 972 865 2219 |
| Web | https://www.reatapharma.com |
Reata Pharmaceuticals Management Efficiency
The company has return on total asset (ROA) of (0.3766) % which means that it has lost $0.3766 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.1239) %, meaning that it created substantial loss on money invested by shareholders. Reata Pharmaceuticals' management efficiency ratios could be used to measure how well Reata Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities.The company currently holds 119.46 M in liabilities with Debt to Equity (D/E) ratio of 2.08, implying the company greatly relies on financing operations through barrowing. Reata Pharmaceuticals has a current ratio of 10.39, suggesting that it is liquid enough and is able to pay its financial obligations when due. Debt can assist Reata Pharmaceuticals until it has trouble settling it off, either with new capital or with free cash flow. So, Reata Pharmaceuticals' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Reata Pharmaceuticals sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Reata to invest in growth at high rates of return. When we think about Reata Pharmaceuticals' use of debt, we should always consider it together with cash and equity.
Reata Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, identifies, develops, and commercializes novel therapeutics for patients with serious or life-threatening diseases. Reata Pharmaceuticals, Inc. was incorporated in 2002 and is headquartered in Plano, Texas. Reata Pharma operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 346 people. Reata Pharmaceuticals (RETA) is traded on NASDAQ Exchange in USA and employs 321 people. Management Performance
| Return On Equity | -1.12 | |||
| Return On Asset | -0.38 |
Reata Pharmaceuticals Leadership Team
Elected by the shareholders, the Reata Pharmaceuticals' board of directors comprises two types of representatives: Reata Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Reata. The board's role is to monitor Reata Pharmaceuticals' management team and ensure that shareholders' interests are well served. Reata Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Reata Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Warren Huff, Chairman of the Board and Presidentident, CEO | ||
| Bhaskar Anand, VP Officer | ||
| Jack Nielsen, Independent Director | ||
| William Rose, Independent Director | ||
| Dawn Bir, Chief Commercial Officer | ||
| James Bass, Independent Director | ||
| Manmeet Soni, CFO COO | ||
| Steve Harman, VP Officer | ||
| Keith Ward, Vice President Chief Development Officer | ||
| Colin Meyer, Chief Medical Officer and Vice President Product Development | ||
| Christian Wigley, VP Officer | ||
| William McClellan, Director | ||
| Michael Wortley, Vice President Chief Legal Officer | ||
| Colin MD, Ex Officer | ||
| Vineet Jindal, Vice President Strategy & Analytics | ||
| Jason Wilson, CFO and Vice President Strategy | ||
| Elaine Castellanos, Consultant | ||
| Dennis Stone, Director | ||
| Dakota Gallivan, VP Officer | ||
| Kent McGaughy, Independent Director |
Reata Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Reata Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -1.12 | |||
| Return On Asset | -0.38 | |||
| Operating Margin | (14.55) % | |||
| Current Valuation | 6.4 B | |||
| Shares Outstanding | 33.59 M | |||
| Shares Owned By Insiders | 4.10 % | |||
| Shares Owned By Institutions | 88.46 % | |||
| Number Of Shares Shorted | 2.6 M | |||
| Price To Earning | (28.13) X | |||
| Price To Book | 285.94 X |
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Reata Pharmaceuticals in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Reata Pharmaceuticals' short interest history, or implied volatility extrapolated from Reata Pharmaceuticals options trading.
Currently Active Assets on Macroaxis
Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in estimate. You can also try the Portfolio Suggestion module to get suggestions outside of your existing asset allocation including your own model portfolios.
Other Consideration for investing in Reata Stock
If you are still planning to invest in Reata Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Reata Pharmaceuticals' history and understand the potential risks before investing.
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| Global Correlations Find global opportunities by holding instruments from different markets | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets |